BioTech Investing in 2022, Jefferies Conference Reflections
The world saw unprecedented growth in healthcare investing in 2021, unlike most industries during the COVID-19 pandemic. The biotech companies that saw the most substantial profits in 2021 did so because they progressed from unproven drugs to phase 3 very quickly. Companies may start small and unloved in the market, but with the discovery/approval of successful drugs, vaccines, and technologies, they quickly become an investor’s target.
The key to rapid clinical phase progression, and ultimate market success, is utilizing highly sophisticated partners, such as Image Analysis Group.
The Jefferies London Healthcare Conference hosted on November 16-19, 2021 featured leading public and private companies in pharmaceuticals, biotechnology, healthcare services, and medical technology from every corner of the world. Pharma and biotech saw record growth in the last year, largely due to COVID’s drive for a vaccine, and the world’s attention being brutally focused on their own personal health and fallibility.
Global precision medicine market investors currently project a compound annual growth rate (CAGR) of 9.0 to 15% for 2021 – 2028.
European and U.S. biotech weathered the financial storm of COVID-19 by more than doubling the return rates of the S&P 500 between January 2020 and January 2021.
Between 2019 – 2020, biotech experienced double-digit growth in venture-capital fundraising, partnerships, developments, and joint ventures, with triple-digit growth in initial public offerings (IPO).
This stems from an aging population that is living longer, with an emphasis on preventative care and oncology. Developments in technology have allowed for greater awareness of general health, which encourages people to investigate preventative health measures. Advances in genomic sequencing allow for customized treatments that will be far superior to current treatments; cue, precision care.
The markets in the Asia-Pacific region are projected to grow at the fastest rate due to reformed drug approval processes and improved patient enrollment protocols. North America, however, still stands as the most lucrative for acquisitions, partnerships, and IPOs.
Looking forward, the combined technological advances in genomics, precision medicine, and artificial intelligence are the keys to joining the ranks of successful biotech companies in 2022. Image Analysis Group has mastered all three to ensure biotech companies reap data as quickly and efficiently as possible.
Interviews with biotech executives and investors agree that to maintain sustained growth, considerable efforts need to be directed at handling the complexity of clinical studies. Having managed over 400 studies, IAG is on track to join the financial elite of 2022.
To set up a consult, please contact bio-partnering@ia-grp.com.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin